VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

Impact · against what's priced in

VNRX sees a positive catalyst as it secures a partner to move its LFT prototype toward commercialization, specifically targeting neonatal sepsis in emerging markets. While the technical correlation with the Nu.Q test was known, the strategic partnership with Missionpharma provides a tangible pathway to market access and low-cost manufacturing.

VNRX+0.60

No priced-in read yet